Nls pharmaceutics ltd. announces expected implementation of 1-for-40 reverse share split

Zurich, switzerland / accesswire / september 25, 2024 / nls pharmaceutics ltd. (nasdaq:nlsp)(nasdaq:nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that a reverse share split of the company's issued and outstanding common shares, par value chf 0.02 per share (the "common shares"), at a ratio of 1-for-40 is expected to be implemented at market open on september 27, 2024 (the "reverse split").
NLSP Ratings Summary
NLSP Quant Ranking